On March 26, 2026, Century Therapeutics, Inc. filed an 8-K with the SEC detailing the effectiveness of a new shelf registration statement on Form S-3, which allows the company to offer up to $150 million in shares through its existing 'at the market' (ATM) equity offering program. This filing replaces a previous registration statement and is part of the company's ongoing efforts to raise capital. The company has already sold approximately $18.4 million worth of shares under this program, leaving about $131.6 million available for future offerings. The filing also includes a prospectus supplement related to the ATM program, indicating a strategic move to enhance liquidity and financial flexibility. The sales agent for this program is Cowen and Company, LLC, which has been engaged since July 2022. This proactive approach to capital management is expected to provide Century Therapeutics with the necessary resources to support its operational and strategic initiatives moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.